News



18/Sep/2020

The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception


18/Sep/2020

Sharp Edge Labs, Inc., http://www.sharpedgelabs.com a drug discovery biology firm, and Creagen Biosciences Inc. http://www.creageninc.com a medicinal chemistry firm, today announced that they have entered into a compound library screening agreement to test Creagen’s medicinal chemistry compound libraries in Sharp Edge Labs’ biological screening assays. The agreement covers all libraries in the Creagen collection and will be applied to Sharp Edge Labs screening assays across therapeutic areas, including, Parkinson’s, Alzheimer’s, Cancer, Cystic Fibrosis and Lysosomal Storage Disorders.

Scott Sneddon, PhD, J.D., President and CEO of Sharp Edge Labs noted that this was a unique opportunity to bring Creagen’s compounds into Sharp Edge Labs’ trafficking assays, and to probe previously unexploited miolecular mechanisms for these diseases. The agreement is open-ended, with additional compounds being made available and additional screening assays being offered by agreement of the companies. “We’re excited to test Creagen’s compounds across a portfolio of first-in-class cellular trafficking assays using our technology’” Sneddon said. “These assays probe novel biology, and expose molecular targets not previously exploited in drug discovery programs.” Sneddon said. Prior to co-founding Sharp Edge Labs, Sneddon was part of the Drug Discovery program at Genzyme Corp., where he oversaw numerous similar compound library screening collaborations.

 


18/Sep/2020

Industrial postdoctoral and researcher scientist positions are available in our medicinal chemistry division.

The project will involve design and optimization of flexible synthetic strategies for preparation of small molecules for oncology research.

The applicants must have:

  • PhD in Organic/medicinal chemistry
  • 1-2 year’s prior postdoctoral experience
  • a competitive publication record
  • strong knowledge in modern synthetic organic/medicinal chemistry and analytical chemistry.

Previous experience working with parallel library synthesis, DNA encoded libraries and antibody-drug-conjugate (ADC) is desirable.

Entry level postdoctoral researchers will be considered and those with advanced postdoctoral training could be eligible for a Research scientist position.

Send resume and contact information with references to: anny@creageninc.com.

Also visit: http://www.creageninc.com


18/Sep/2020

Raj Rajur attends TiECON East Conference as Charter Member together with Governor Deval Patrick. Several Pictures from the Event:

MA CRO/CMO Symposium: Accelerating Drug Development
A One Day Symposium Presented by MassBio’s Massachusetts CRO CMO Committee
Symposium will feature addresses by:
Timothy Murray, Lieutenant Governor State of Massachusetts
The Conference Center at Bentley University, 75 Forest Street, LaCava 300, Waltham, MA 02452
March 6, 2012 7:30 a.m. to 4:00 p.m.
More Details


18/Sep/2020

1) Press Release (PDF)
2) 
Patent publication

Dr. Rajur chaired the medicinal chemistry symposium of the Northeastern section of American Chemical Society, Marriott Hotel, Burlington, MA, on September 10th, 2009. Symposium title “Recent Developments in Neurodegenerative diseases”

The Boston Society and NESACS applied pharmaceutical sciences and medicinal chemistry symposium titled”Frontiers in Strategies and Technologies to enrich pharmaceutical pipelines” held on
May 21-22, 2009 at the Merck Research Laboratories Boston Amphitheater, Boston, MA. was Hosted and co-sponsored in part by CreaGen Biosciences, Inc.

3rd Annual Advances In Chemical Sciences Symposium held on April 10, 2009 at the Royal Sonesta Hotel in Cambridge, MA. was Hosted and co-sponsored in part by CreaGen Biosciences, Inc.




Subscribe


Sign up for CreaGen Inc newsletter to receive all the news.




Social networks



Twitter

#WeCare




Contact us




Send us an email

rrajur@creageninc.com



Subscribe


Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.




Social networks



Twitter

#WeCare





© CreaGen Inc 2019. All rights reserved. Designed by Inqude



© CreaGen Inc 2019. All rights reserved. Designed by Inqude